Working… Menu
Trial record 21 of 415 for:    Gonadotrophin, Chorionic AND Choriogonadotropin Alfa

hCG Supplementation in Frozen-Thawed Embryo Transfer Cycle

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00398229
Recruitment Status : Completed
First Posted : November 10, 2006
Last Update Posted : January 1, 2009
Information provided by:
Hadassah Medical Organization

Brief Summary:
The implantation rate after frozen-thawed embryo transfer cycles depends mostly on the receptivity of the endometrium and the embryo quality.The effects of human chorionic gonadotropins (hCG) on the endometrium have been investigated for several years. hCG was shown to up-regulate gene expression during the differentiation of human endometrial stromal cells into decidua. The aim of our study was to assess the benefit of hCG supplementation throughout the secretory phase of artificial frozen-thawed embryo transfer cycles.

Condition or disease Intervention/treatment Phase
Fertility Agents, Female Drug: s.c. human chorionic gonadotropin (Ovitrelle) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Benefit of Human Chorionic Gonadotropin (hCG) Supplementation Throughout the Secretory Phase of Frozen-Thawed Embryo Transfer Cycles
Study Start Date : November 2006
Actual Study Completion Date : May 2008

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Active Comparator: A
receiving hCG injection
Drug: s.c. human chorionic gonadotropin (Ovitrelle)
S.C. Ovitrelle 250 mcg once

Placebo Comparator: B Drug: s.c. human chorionic gonadotropin (Ovitrelle)
S.C. Ovitrelle 250 mcg once

Primary Outcome Measures :
  1. implantation rate [ Time Frame: 4 weeks ]
  2. pregnancy rate [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • all women on frozen-thawed embryo-transfer cycle

Exclusion Criteria:

  • any allergy to injection of human chorionic gonadotropin before

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00398229

Layout table for location information
Hadassah Medical center
Jerusalem, Israel
Sponsors and Collaborators
Hadassah Medical Organization
Layout table for investigator information
Principal Investigator: Assaf Ben-Meir, MD Hadassah Medical Organization

Layout table for additonal information
Responsible Party: Arik Tzukert, Hadassah Medical Center Identifier: NCT00398229     History of Changes
Other Study ID Numbers: freezehcg-HMO-CTIL
First Posted: November 10, 2006    Key Record Dates
Last Update Posted: January 1, 2009
Last Verified: November 2007
Keywords provided by Hadassah Medical Organization:
In-Vitro Fertilization
human chorionic gonadotropin
frozen-thawed embryo transfer
implantation rate
Additional relevant MeSH terms:
Layout table for MeSH terms
Chorionic Gonadotropin
Reproductive Control Agents
Physiological Effects of Drugs